Management ChangeJul 31, 2026, 04:57 PM
Quince Therapeutics Announces Conditional CEO, CFO, COO Appointments
AI Summary
Quince Therapeutics, Inc. announced that its CEO and CMO, Dirk Thye, and COO, CBO, and CCO, Brendan Hannah, tendered conditional resignations on July 29, 2026. Their resignations are contingent upon stockholder approval of three proposals at the upcoming Special Meeting, anticipated on September 25, 2026, related to the Orphai acquisition and PIPE financing. Concurrently, the Board conditionally appointed Brigette Roberts as CEO, John Militello as CFO, and Keith Fandrick as COO, all effective upon the same stockholder approvals. The departing officers remain eligible for retention bonuses and severance.
Key Highlights
- CEO Dirk Thye and COO Brendan Hannah tendered conditional resignations on July 29, 2026.
- Resignations are effective two business days after the Special Meeting (anticipated September 25, 2026).
- Resignations are contingent on stockholder approval of three proposals related to the Orphai acquisition and PIPE financing.
- Brigette Roberts conditionally appointed CEO, effective upon stockholder approvals.
- John Militello conditionally appointed CFO, effective upon stockholder approvals.
- Keith Fandrick conditionally appointed COO, effective upon stockholder approvals.
- Departing officers are eligible for previously disclosed retention bonuses and severance.
Price Impact
More from QNCX